STOCK TITAN

Ameriprise discloses 8.4% Pasithea Therapeutics (NASDAQ: KTTA) stake

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Ameriprise Financial, Inc. and Columbia Management Investment Advisers, LLC filed a Schedule 13G reporting beneficial ownership of 1,930,128 shares of Pasithea Therapeutics Corp. common stock, equal to 8.4% of the class as of 12/31/2025.

Both entities report zero sole voting or dispositive power and shared voting and dispositive power over all reported shares. They state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pasithea Therapeutics.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Ameriprise Financial, Inc.
Signature:/s/ Michael G. Clarke
Name/Title:Michael G. Clarke, Senior Vice President, North America Head of Operations & Investor Services
Date:02/17/2026
Columbia Management Investment Advisers, LLC
Signature:/s/ Michael G. Clarke
Name/Title:Michael G. Clarke, Senior Vice President, North America Head of Operations & Investor Services
Date:02/17/2026

Comments accompanying signature: Contact Information Charles Chiesa VP Fund Treasurer Global Operations and Investor Services Telephone: 617-385-9593
Exhibit Information

Exhibit Index Exhibit I Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company. Exhibit II Joint Filing Agreement

FAQ

What stake in Pasithea Therapeutics (KTTA) did Ameriprise report?

Ameriprise Financial and its adviser reported beneficial ownership of 1,930,128 Pasithea Therapeutics common shares, representing 8.4% of the outstanding class as of 12/31/2025. All reported shares are subject to shared, not sole, voting and dispositive power.

Who are the reporting persons in this Pasithea (KTTA) Schedule 13G?

The Schedule 13G lists Ameriprise Financial, Inc. and Columbia Management Investment Advisers, LLC as reporting persons. Ameriprise is the parent of Columbia, and Ameriprise may be deemed to beneficially own the same 1,930,128 shares reported by Columbia through its advisory relationship.

Is Ameriprise’s Pasithea (KTTA) position a passive investment?

Yes. The certification states the Pasithea securities were acquired and are held in the ordinary course of business, not to change or influence control of the issuer, and not in connection with any transaction intended to affect control, other than limited nomination-related activities allowed by regulation.

How much voting power over Pasithea (KTTA) shares do Ameriprise and Columbia have?

They report shared voting power over 1,930,128 Pasithea common shares and no sole voting power. They also report shared dispositive power over the same number of shares and no sole dispositive power, indicating joint authority rather than exclusive control over these holdings.

What ownership percentage of Pasithea (KTTA) does 1,930,128 shares represent?

The 1,930,128 Pasithea Therapeutics common shares represent 8.4% of the outstanding class. This level of beneficial ownership triggers Schedule 13G reporting, which is typically used by investors taking a passive, non‑control intent position in a public company’s equity.

Did Ameriprise or Columbia disclaim beneficial ownership of Pasithea (KTTA) shares?

Yes. The Schedule 13G notes that Ameriprise Financial and Columbia Management Investment Advisers each disclaim beneficial ownership of any shares reported, even though Ameriprise may be deemed to beneficially own the Pasithea shares reported by Columbia as its parent company.
Pasithea Therapeutics Corp

NASDAQ:KTTA

KTTA Rankings

KTTA Latest News

KTTA Latest SEC Filings

KTTA Stock Data

16.40M
22.72M
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI BEACH